Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A thin-cap fibroatheroma with a large necrotic core and macrophage infiltration marks the vulnerable plaque. Fibroblast activating protein (FAP) is an active serine protease, which can degrade type I collagen, potentially thinning the fibrous cap. Thus we speculate that atherosclerotic plaque could be imaged with 68Ga-FAPI PET/MR.
A thin-cap fibroatheroma with a large necrotic core and macrophage infiltration marks the vulnerable plaque. Fibroblast activating protein (FAP) is an active serine protease, which can degrade type I collagen, potentially thinning the fibrous cap. Previous ex vivo analysis of human aortic atheromata revealed that FAP was expressed in atherosclerotic plaques, and higher FAP expression was detected in thin fibrous caps than thick caps. Constitutive Fap deletion in atherosclerosis-prone mice models could reduce plaque formation and improve plaque stability with increased fibrous cap thickness. Thus we speculate that atherosclerotic plaque could be imaged with 68Ga-FAPI PET/MR.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 68Ga-FAPI, PET/MR | Experimental | inject 68Ga-FAPI,and then perform PET/MR |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 68Ga-FAPI | Drug | intravenously injected with 68Ga-FAPI |
|
| Measure | Description | Time Frame |
|---|---|---|
| Diagnostic performance | Diagnostic performance of 68Ga-FAPI PET/MR for intracranial or carotid atherosclerosis | through study completion, an average of 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| SUVmax | The difference of SUVmax between asymptomatic and symptomatic atherosclerotic patients | through study completion, an average of 2 years |
| FAPI expression | The correlation of SUVmax and pathological FAPI expression |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Li Huo, M.D. | Contact | 86-10-69155537 | huoli@pumch.cn |
| Name | Affiliation | Role |
|---|---|---|
| Qiao Yang, M.D. | Peking Union Medical College Hospital | Principal Investigator |
| Meiqi Wu, M.D. | Peking Union Medical College Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Peking Union Medical College Hospital | Recruiting | Beijing | 100005 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D050197 | Atherosclerosis |
| ID | Term |
|---|---|
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000707753 | 68Ga-FAPI |
Not provided
Not provided
Not provided
68Ga-FAPI PET/MR
Not provided
Not provided
Not provided
Not provided
| through study completion, an average of 2 years |